DIA241129P409000
- 0.03
- 0.000.00%
SPDR Dow Jones Industrial Average Trust Newsroom
Hawkish or Dovish? Exploring Clues from FOMC Minutes and Upcoming Economic Data
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
How S&P 500 Tends to Perform During Thanksgiving Week and Into New Year's Eve
Treasury Yields Fall as Traders Await PCE Inflation Data
Beware of inflation rising again! Goldman Sachs outlook for global investment in 2025: US stocks are too expensive and under-allocated, gold remains the best hedge option
Considering the prospects of upside risks such as Trump's tariffs, geopolitical tensions, etc., Goldman Sachs recommends investors to maintain a moderate pro-risk stance in asset allocation, while balancing in a multi-asset investment portfolio: reducing the allocation of highly concentrated and overvalued US stocks, focusing on Asian stocks such as Japan, short-term government bonds, US dollars, and gold which remains the best hedging tool.
The bull market continues! Morgan Stanley projects that the US stock market will reach 6,500 points by the end of 2025, with a focus on quality cyclical stocks.
Daiwa believes that the s&p 500, represented by high-quality stocks, will benefit from the Fed's rate cut cycle, stabilization of business indicators, policy mix, and uncertainty in economic data. However, considering that specific policies have not yet been introduced, U.S. stocks have been severely overbought, and next year's market is unlikely to "rise in a straight line," the key will be to see the Trump administration's measures in cutting fiscal spending.
The strong upward trend of U.S. stocks has sparked a wave of IPO recovery, bringing new hope to private equity.
The return of private equity-backed initial public offerings (IPOs) to the United States is expected to make a comeback.
Wall Street didn't prepare in vain! Trump hasn't taken office yet, but "tweeting to govern" has already begun.
① Although Trump's primary platform for social media expression may have shifted back from Twitter to his own platform, Truth Social, his habit of "governing through Twitter" has clearly not changed; ② This has led many Wall Street institutions to register for Truth Social accounts early, both before and after the election results were announced, and considering it as a precautionary measure in their strategy tracking models has proven to be a worthwhile effort!
OpenAI's Sora Video Model Leak Exposes Deep Rift With Artists — Unpaid R&D, PR Puppets, And Content Approval Fury: What You Need To Know
11/27 [Strong and Weak Materials]
[Bullish and Bearish Materials] Bullish materials: Dow Jones Industrial Average is up (44860.31, +123.74); Nasdaq Composite Index is up (19174.30, +119.46); VIX index is down (14.10, -0.50); Active share buybacks; Request from the Tokyo Stock Exchange for enhancing corporate value. Bearish materials: Nikkei Average is down (38442.00, -338.14); 1 dollar = 153.10-20 yen; Chicago Nikkei futures are down (38330, -160); SOX index is down (4927.56, -
Back Up The Truck Buying Opportunities May Be Ahead, Record Bets On Bitcoin Drop
Stock Futures Are Little Changed as Wall Street Awaits Fed's Preferred Inflation Reading
U.S. stocks closed: The Dow and S&P reached all-time highs, while general motors plunged nearly 9%.
① Most technology giants rose, only Tesla fell; ② Eli Lilly and Co rose by 4.5%, as Biden proposed health insurance coverage for weight loss drugs; ③ The Chinese concept stock Jinlong Index fell by 0.8%, Nio fell by 7.7%; ④ Apple proposed to increase investment by 0.1 billion US dollars to seek to lift the sales ban, but was rejected by the Indonesian government.
How Major US Stock Indexes Fared Tuesday, 11/26/2024
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
How Is The Market Feeling About Visa?
19,000 Bans And Counting, But Players Say Cheating Still Dominates Call Of Duty Black Ops 6
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?